Jens Sandahl Christiansen

Author PubWeight™ 73.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003 1.93
2 Clinical and epidemiological description of aortic dissection in Turner's syndrome. Cardiol Young 2006 1.86
3 Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002 1.76
4 GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013 1.74
5 Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res 2008 1.72
6 Continuous glucose monitoring in interstitial subcutaneous adipose tissue and skeletal muscle reflects excursions in cerebral cortex. Diabetes 2005 1.44
7 OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant 2011 1.44
8 A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003 1.30
9 Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003 1.18
10 Nocturnal hypertension and impaired sympathovagal tone in Turner syndrome. J Hypertens 2006 1.13
11 Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007 1.08
12 The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project: rationale and planned nationwide studies of genetic predictors, physical exercise, and individualized pharmacological treatment. Clin Epidemiol 2012 0.99
13 Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab 2007 0.98
14 Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 2002 0.97
15 Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 2007 0.94
16 Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol 2006 0.94
17 Preferential stimulation of abdominal subcutaneous lipolysis after prednisolone exposure in humans. Obes Res 2002 0.93
18 The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. Eur J Endocrinol 2004 0.92
19 Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. Am J Physiol Endocrinol Metab 2003 0.92
20 Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs 2012 0.91
21 The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone. J Clin Endocrinol Metab 2003 0.91
22 Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013 0.90
23 IDegAsp: a novel soluble insulin analogs combination. Expert Opin Biol Ther 2012 0.89
24 Mortality and GH deficiency: a nationwide study. Eur J Endocrinol 2007 0.89
25 Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab 2003 0.89
26 Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 2002 0.88
27 Diabetes as a case study of chronic disease management with a personalized approach: the role of a structured feedback loop. Diabetes Res Clin Pract 2012 0.88
28 One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study. J Clin Endocrinol Metab 2010 0.88
29 Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Horm IGF Res 2010 0.88
30 Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study. Pediatrics 2002 0.87
31 Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: results from The Danish National Study on Posttraumatic Hypopituitarism. J Clin Endocrinol Metab 2013 0.86
32 Abnormalities of the major intrathoracic arteries in Turner syndrome as revealed by magnetic resonance imaging. Cardiol Young 2010 0.86
33 A multistep algorithm for processing and calibration of microdialysis continuous glucose monitoring data. Diabetes Technol Ther 2013 0.86
34 Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 2011 0.86
35 Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2010 0.85
36 Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab 2002 0.85
37 Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 2010 0.85
38 Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: a cross-sectional study. Cardiovasc Diabetol 2013 0.84
39 Assessment of postprandial glucose excursions throughout the day in newly diagnosed type 2 diabetes. Diabetes Technol Ther 2012 0.84
40 Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD. Eur J Endocrinol 2012 0.84
41 Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting. Eur J Endocrinol 2004 0.84
42 Effect of growth hormone and 17beta-oestradiol treatment on metabolism and body composition in girls with Turner syndrome. Clin Endocrinol (Oxf) 2005 0.83
43 Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial. Eur J Endocrinol 2007 0.83
44 Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Horm IGF Res 2011 0.83
45 Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 2005 0.82
46 Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect 2014 0.82
47 Changes in glycaemic control are related to the systolic function in type 1 diabetes mellitus. Scand Cardiovasc J 2007 0.82
48 Morbidity and GH deficiency: a nationwide study. Eur J Endocrinol 2008 0.81
49 The management of adult growth hormone deficiency syndrome. Expert Opin Pharmacother 2008 0.81
50 Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diabetes Sci Technol 2007 0.81
51 Glycemia, lipidemia and systolic left ventricular function evaluated by myocardial strain rate: a tissue Doppler echocardiographic study. Ultrasound Med Biol 2007 0.81
52 Marked reductions in bioactive insulin-like growth factor I (IGF-I) during hemodialysis. Growth Horm IGF Res 2009 0.81
53 Sex steroids and the growth hormone/insulin-like growth factor-I axis in adults. Horm Res 2005 0.81
54 The GH-IGF-IGFBP axis is changed in Turner syndrome: partial normalization by HRT. Growth Horm IGF Res 2006 0.80
55 The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 2004 0.80
56 Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Eur J Endocrinol 2012 0.79
57 Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol (Oxf) 2007 0.79
58 Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 2006 0.79
59 Quantitative liver functions in Turner syndrome with and without hormone replacement therapy. Eur J Endocrinol 2007 0.79
60 A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study. Diabetes Technol Ther 2012 0.78
61 The effect of growth hormone on the insulin-like growth factor system during fasting. J Clin Endocrinol Metab 2003 0.78
62 Evaluation of growth hormone stimulation tests in cured acromegalic patients. Growth Horm IGF Res 2003 0.78
63 Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients. Growth Horm IGF Res 2002 0.78
64 Biochemical definitions of disease activity in acromegaly. Growth Horm IGF Res 2003 0.78
65 OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 2008 0.78
66 Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clin Endocrinol (Oxf) 2003 0.78
67 Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. Eur J Endocrinol 2005 0.78
68 Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections: Implications for detection of GH abuse. Growth Horm IGF Res 2011 0.78
69 The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults. J Clin Endocrinol Metab 2002 0.77
70 Vitamin C treatment reduces transcapillary escape rate of albumin in type 1 diabetes. Eur J Intern Med 2004 0.77
71 Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. Eur J Endocrinol 2005 0.77
72 Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. J Clin Endocrinol Metab 2002 0.77
73 Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men. J Appl Physiol (1985) 2003 0.77
74 Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement. Indian J Endocrinol Metab 2011 0.77
75 Interindividual and intraindividual variations in postprandial glycemia peak time complicate precise recommendations for self-monitoring of glucose in persons with type 1 diabetes mellitus. J Diabetes Sci Technol 2012 0.77
76 A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design. BMC Endocr Disord 2012 0.76
77 Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort. BMC Endocr Disord 2014 0.76
78 Accuracy evaluation of a new real-time continuous glucose monitoring algorithm in hypoglycemia. Diabetes Technol Ther 2014 0.76
79 Protein metabolism in Turner syndrome and the impact of hormone replacement therapy. Clin Endocrinol (Oxf) 2007 0.76
80 Hypertension and Diabetic Nephropathy. Endocr Dev 2016 0.76
81 Serum insulin aspart concentrations following high-dose insulin aspart administered directly into the duodenum of healthy subjects: an open-labeled, single-blinded, and uncontrolled exploratory trial. J Diabetes Sci Technol 2009 0.75
82 Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes. BMC Endocr Disord 2014 0.75
83 A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study. Basic Clin Pharmacol Toxicol 2009 0.75
84 [Guidelines on diagnosis of type 2 diabetes. Investigation, diagnosis and glucose measurement]. Ugeskr Laeger 2003 0.75
85 [Sexual dysfunction in diabetes mellitus]. Ugeskr Laeger 2002 0.75
86 [Insulin pump treatment in Denmark]. Ugeskr Laeger 2004 0.75
87 [In Process Citation]. Ugeskr Laeger 2014 0.75
88 Assessment of hydration by means of bioelectrical impedance and arm muscle area during growth hormone (GH) replacement therapy: A prospective study of 130 GH-deficient patients. Growth Horm IGF Res 2007 0.75
89 Long-acting growth hormone. Paediatr Drugs 2013 0.75
90 Interaction between exogenous insulin, endogenous insulin, and glucose in type 2 diabetes patients. Diabetes Technol Ther 2015 0.75
91 Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study. Diabetes Metab Res Rev 2014 0.75
92 Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clin Endocrinol (Oxf) 2002 0.75
93 Measurement of free GH and bioactive IGF-I in non-diabetic haemodialysis patients treated with GH for 7 days. Nephrol Dial Transplant 2012 0.75
94 Inhibin A and B in adolescents and young adults with Turner's syndrome and no sign of spontaneous puberty. Hum Reprod 2002 0.75
95 Continuation of growth hormone therapy versus placebo in transition-phase patients with growth hormone deficiency: impact on body composition, insulin sensitivity, and thyroid function. J Pediatr Endocrinol Metab 2002 0.75